Armata Pharmaceuticals Inc (ARMP)

May 02, 2025

Armata Pharmaceuticals secures additional DoD funding - Investing.com

May 02, 2025

May 01, 2025

Armata Pharmaceuticals (ARMP) Secures Additional $4.65M for Clin - GuruFocus

May 01, 2025

May 01, 2025

Armata Pharmaceuticals Receives $4.65 Million of Additional Non- - GuruFocus

May 01, 2025

May 01, 2025

Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - Yahoo Finance

May 01, 2025

Apr 28, 2025

New Strong Sell Stocks for April 28th - The Globe and Mail

Apr 28, 2025

Apr 02, 2025

10 Best Healthcare Stocks to Invest In (May 2025) - Securities.io

Apr 02, 2025

Apr 01, 2025

Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Expands By 28.3% - Defense World

Apr 01, 2025

Mar 31, 2025

Bacteriophage Therapy Market Future Business Opportunities - openPR

Mar 31, 2025

Mar 24, 2025

HC Wainwright Comments on Armata Pharmaceuticals Q1 Earnings - Defense World

Mar 24, 2025

Mar 21, 2025

Armata Pharmaceuticals Inc (ARMP) Q4 2024 Earnings: EPS of $0.07 - GuruFocus

Mar 21, 2025

Mar 21, 2025

Armata Pharmaceuticals reports Q4 EPS (23c) vs (55c) last year - MSN

Mar 21, 2025

Mar 21, 2025

Armata Pharmaceuticals Inc. (ARMP) reports earnings - Quartz

Mar 21, 2025

Mar 20, 2025

Armata Pharmaceuticals Announces Fourth Quarter And Full-Year 2024 Results And Provides Corporate Update - MarketScreener

Mar 20, 2025

Mar 20, 2025

Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update - PR Newswire

Mar 20, 2025

Mar 18, 2025

Armata Pharmaceuticals (ARMP) Projected to Post Quarterly Earnings on Thursday - The AM Reporter

Mar 18, 2025

Mar 12, 2025

Armata Pharmaceuticals secures $10 million credit By Investing.com - Investing.com Australia

Mar 12, 2025

Mar 12, 2025

Armata Pharmaceuticals secures $10 million credit - Investing.com India

Mar 12, 2025

Mar 12, 2025

Armata Pharmaceuticals Secures $10M Loan for Clinical Trials - TipRanks

Mar 12, 2025

Mar 12, 2025

Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - Eastern Progress

Mar 12, 2025

Mar 11, 2025

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit - Quantisnow

Mar 11, 2025

Feb 18, 2025

Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Rises By 7.5% - MarketBeat

Feb 18, 2025

Feb 02, 2025

Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Grows By 203.3% - MarketBeat

Feb 02, 2025

Jan 27, 2025

Chronic Pulmonary Infections Pipeline 2024: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Teva Pharma, Merck, F. Hoffmann-La Roche, Novartis, GlaxoSmithKline, AstraZeneca - The Globe and Mail

Jan 27, 2025

Jan 23, 2025

Phage Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight - GlobeNewswire Inc.

Jan 23, 2025

Jan 23, 2025

Phage Therapies Clinical Trial Pipeline Shows Potential - GlobeNewswire

Jan 23, 2025

Jan 14, 2025

Armata Pharmaceuticals (STU:TG1N) PS Ratio : (As of Jan. 14, 2025) - GuruFocus.com

Jan 14, 2025

Jan 14, 2025

Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Short Interest Update - MarketBeat

Jan 14, 2025

Jan 08, 2025

Armata Pharmaceuticals Announces $35 Million Secured Credit Agre - GuruFocus.com

Jan 08, 2025

Dec 27, 2024

Short Interest in Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP) Grows By 125.9% - MarketBeat

Dec 27, 2024

Dec 21, 2024

Ampliphi Biosciences (NYSEAMERICAN:APHB) Announces Positive Results from Phase 2 Tailwind Study - Defense World

Dec 21, 2024

Dec 21, 2024

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Earns “Buy” Rating from HC Wainwright - Defense World

Dec 21, 2024

Dec 20, 2024

Armata Pharma’s inhaled AP-PA02 shows positive results in Phase 2 study - Yahoo Finance

Dec 20, 2024

Dec 19, 2024

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Given Buy Rating at HC Wainwright - MarketBeat

Dec 19, 2024

Dec 19, 2024

Armata Pharmaceuticals Reports Positive Phase 2 Study Results - TipRanks

Dec 19, 2024

Dec 19, 2024

Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - PR Newswire

Dec 19, 2024

Dec 17, 2024

ARMP Stock Touches 52-Week Low at $1.98 Amid Market Challenges - Investing.com

Dec 17, 2024

Dec 15, 2024

Suparna Mishra Sarkar - Los Angeles Times

Dec 15, 2024

Dec 11, 2024

Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia - The Eastern Progress Online

Dec 11, 2024

Dec 10, 2024

Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting - The Eastern Progress Online

Dec 10, 2024

Dec 07, 2024

Armata Pharmaceuticals Announces Appointment of Life Sciences Accounting and Finance Veteran David House as SVP of Finance and Principal Financial Officer - The Eastern Progress Online

Dec 07, 2024

Dec 01, 2024

Armata Pharmaceuticals Announces Presentation at the 6th Annual Bacteriophage Therapy Summit - GuruFocus.com

Dec 01, 2024

Nov 22, 2024

Armata Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com

Nov 22, 2024

Nov 21, 2024

Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update - GuruFocus.com

Nov 21, 2024